What is Zacks Research’s Forecast for REVB Q1 Earnings?

Revelation Biosciences, Inc. (NASDAQ:REVB) – Investment analysts at Zacks Research issued their Q1 2027 earnings per share (EPS) estimates for Revelation Biosciences in a research note issued on Friday, November 6th. Zacks Research analyst B. Sorensen anticipates that the company will post earnings of ($4.71) per share for the quarter. The consensus estimate for Revelation Biosciences’ current full-year earnings is ($35.08) per share. Zacks Research also issued estimates for Revelation Biosciences’ Q2 2027 earnings at ($4.10) EPS, Q3 2027 earnings at ($4.05) EPS and Q4 2027 earnings at ($4.92) EPS.

Separately, Weiss Ratings raised Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Revelation Biosciences Trading Up 5.4%

Shares of NASDAQ REVB opened at $4.15 on Thursday. The firm has a market cap of $2.84 million, a PE ratio of -0.10 and a beta of -0.13. Revelation Biosciences has a 1-year low of $3.08 and a 1-year high of $40.60. The company has a fifty day moving average price of $5.27 and a 200 day moving average price of $7.52.

Revelation Biosciences (NASDAQ:REVB) last posted its earnings results on Thursday, November 5th. The company reported ($5.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.16) by $0.24.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases. Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.